{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:24:02Z","timestamp":1787257442973,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI155716"],"award-info":[{"award-number":["R01AI155716"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA298839"],"award-info":[{"award-number":["R01CA298839"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jbc.2026.113269","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:19:33Z","timestamp":1781911173000},"page":"113269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody glyco-optimization and site-specific conjugation enhance the immune-stimulating activity of antibody\u2013TLR ligand conjugates"],"prefix":"10.1016","volume":"302","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-6918","authenticated-orcid":false,"given":"Xianyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoxian","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0312-8574","authenticated-orcid":false,"given":"Helena","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaryta","family":"Gomozkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2076-609X","authenticated-orcid":false,"given":"Guangming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4293-5819","authenticated-orcid":false,"given":"Lai-Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2026.113269_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2026.113269_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113269_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113269_bib4","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin B"},{"key":"10.1016\/j.jbc.2026.113269_bib5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2026.113269_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2026.113269_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107160","article-title":"When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?","volume":"203","author":"Fu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jbc.2026.113269_bib8","article-title":"Antibody-pattern recognition receptor agonist conjugates: a promising therapeutic strategy for cancer","volume":"6","author":"Xu","year":"2022","journal-title":"Adv. Biol. (Weinh)"},{"key":"10.1016\/j.jbc.2026.113269_bib9","doi-asserted-by":"crossref","first-page":"16222","DOI":"10.1021\/acs.jmedchem.4c00804","article-title":"Discovery and evaluation of TLR-targeted immune agonists","volume":"67","author":"Chernyak","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jbc.2026.113269_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282831","article-title":"Antibody conjugates for targeted delivery of toll-like receptor 9 agonist to the tumor tissue","volume":"18","author":"Corogeanu","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113269_bib11","doi-asserted-by":"crossref","first-page":"10715","DOI":"10.1021\/acs.jmedchem.3c00907","article-title":"Discovery and optimization of a STING agonist platform for application in antibody drug conjugates","volume":"66","author":"Duvall","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jbc.2026.113269_bib12","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1021\/acs.molpharmaceut.2c00392","article-title":"Design and characterization of immune-stimulating Imidazo[4,5-c]quinoline antibody-drug conjugates","volume":"19","author":"Fang","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jbc.2026.113269_bib13","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/acs.bioconjchem.5b00302","article-title":"Targeted activation of toll-like receptors: conjugation of a toll-like receptor 7 agonist to a monoclonal antibody maintains antigen binding and specificity","volume":"26","author":"Gadd","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jbc.2026.113269_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109180","article-title":"Increased macrophage phagocytic activity with TLR9 agonist conjugation of an anti- Borrelia burgdorferi monoclonal antibody","volume":"246","author":"Jahanbani","year":"2023","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jbc.2026.113269_bib15","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1021\/acs.accounts.0c00337","article-title":"Chemical strategies to enhance the therapeutic efficacy of toll-like receptor agonist based cancer immunotherapy","volume":"53","author":"Lee","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jbc.2026.113269_bib16","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1038\/s41467-024-49932-4","article-title":"Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses","volume":"15","author":"Malli Cetinbas","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113269_bib17","doi-asserted-by":"crossref","first-page":"15756","DOI":"10.1021\/acs.jmedchem.4c01384","article-title":"Design and optimization of selectivity-tunable toll-like receptor 7\/8 agonists as novel antibody-drug conjugate payloads","volume":"67","author":"Patel","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jbc.2026.113269_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s43018-020-00152-x","article-title":"ISACs take a toll on tumors","volume":"2","author":"Demaria","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.jbc.2026.113269_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.jbc.2026.113269_bib20","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-OT-03-02","article-title":"Abstract OT-03-02: phase 1\/2 study of a novel HER2 targeting TLR7\/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors","volume":"81","author":"Dumbrava","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2026.113269_bib21","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1158\/1538-7445.AM2021-1738","article-title":"Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity","volume":"81","author":"Duvall","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2026.113269_bib22","first-page":"A426","article-title":"393 A phase 1\/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers","volume":"9","author":"Klempner","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jbc.2026.113269_bib23","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2020.38.15_suppl.3110","article-title":"SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist","volume":"38","author":"Metz","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113269_bib24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/glycob\/cwz065","article-title":"The history of IgG glycosylation and where we are now","volume":"30","author":"Cobb","year":"2020","journal-title":"Glycobiology"},{"key":"10.1016\/j.jbc.2026.113269_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/glycob\/cwz068","article-title":"A synopsis of recent developments defining how N-glycosylation impacts immunoglobulin G structure and function","volume":"30","author":"Yamaguchi","year":"2020","journal-title":"Glycobiology"},{"key":"10.1016\/j.jbc.2026.113269_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.987151","article-title":"Role of N-Glycosylation in Fc\u03b3RIIIa interaction with IgG","volume":"13","author":"Van Coillie","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2026.113269_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2020.113615","article-title":"Recent progress in transglutaminase-mediated assembly of antibody-drug conjugates","volume":"595","author":"Schneider","year":"2020","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jbc.2026.113269_bib28","doi-asserted-by":"crossref","first-page":"16508","DOI":"10.1074\/jbc.M116.738765","article-title":"Glycosynthase mutants of endoglycosidase S2 show potent transglycosylation activity and remarkably relaxed substrate specificity for antibody glycosylation remodeling","volume":"291","author":"Li","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113269_bib29","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1073\/pnas.1702173114","article-title":"Modulating IgG effector function by Fc glycan engineering","volume":"114","author":"Li","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.113269_bib30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1021\/bc400574z","article-title":"Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates","volume":"25","author":"Dennler","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jbc.2026.113269_bib31","doi-asserted-by":"crossref","first-page":"9995","DOI":"10.1002\/anie.201004243","article-title":"Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase","volume":"49","author":"Jeger","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.jbc.2026.113269_bib32","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1021\/acs.bioconjchem.0c00061","article-title":"Site-specific conjugation of native antibodies using engineered microbial transglutaminases","volume":"31","author":"Dickgiesser","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jbc.2026.113269_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/acs.bioconjchem.4c00013","article-title":"Site-specific conjugation of native antibody: transglutaminase-mediated modification of a conserved glutamine while maintaining the primary sequence and core Fc glycan via trimming with an endoglycosidase","volume":"35","author":"Sadiki","year":"2024","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jbc.2026.113269_bib34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/978-1-4939-8648-4_19","article-title":"Chemoenzymatic defucosylation of therapeutic antibodies for enhanced effector functions using bacterial alpha-fucosidases","volume":"1827","author":"Li","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jbc.2026.113269_bib35","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1073\/pnas.1108455108","article-title":"Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose","volume":"108","author":"Ferrara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.113269_bib36","article-title":"Selective fluorination of Fc glycans enhances antibody-mediated effector functions","volume":"123","author":"Wang","year":"2026","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.113269_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.50","article-title":"Phenotypic and functional study of human plasmacytoid dendritic cells","volume":"1","author":"Li","year":"2021","journal-title":"Curr. Protoc."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826021411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826021411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T19:37:19Z","timestamp":1787254639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925826021411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0021925826021411"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113269","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody glyco-optimization and site-specific conjugation enhance the immune-stimulating activity of antibody\u2013TLR ligand conjugates","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113269","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"113269"}}